Menu
Home
TMU
FAQ
Sitemap
正體中文
News
Announcements
Events
Business
FAQ
FAQ: IRB
FAQ: Clinical Trial
FAQ: Biobank
Charges
Public Area
About OHR
OHR Overview
Dean
OHR Members
Department
JIRB Administration Section
Data Safety Managing Section
Joint Clinical Research Center
Joint Biobank
Business
Clinical Trial
Clinical Trial Agreement
Investigator-Initiated Trial
Project Writing Consultation
Ongoing Clinical Trials
Biobank
Biobank Application
Charges
TMU-JIRB
About TMU-JIRB
Introduction
Members
SOP
Application System
TMU-eJIRB System
IRB Account Controller Application
Application Process
Charges
Meeting Date
FAQs
Download
Forms
Clinical Trial
Regulation
TMU Regulation
Domestic Regulation
Related Regulation
Links
Online Portals
TMU Online Resources
External Online Resources
Affiliated Hospitals
REACTA 2024
Contact
Contact Info
Website Feedback Form
Home
Ongoing Clinical Trials
Ongoing Clinical Trials
Indication
All
overweight and obesity
Esophagus:process
Knee Osteoarthritis (KOA)
Pancreatic Cancer
Dermatosis/skin disease
Cell Therapy
Asthma
Solid tumors
Chronic obstructive pulmonary disease (COPD)
Rhinosinusitis
Lung Cancer
Endometriosis
Diabetes
Hepatitis B or D Infection
Hepatocellular Carcinoma (HCC)
Pregnant Women
Non-Alcoholic Fatty Liver
Healthy Volunteer
Systemic Lupus Erythematosus
Sjögren’s syndrome (NEPTUNUS-2)
Gout
COVID-20
Hemodialysis
Chronic Kidney Disease
Chronic Kidney Disease
heart failure
major adverse cardiovascular events
Coronary Syndrome
Spinal Cord Injuries (SCI)
High Blood Pressure/Hypertension
Hypercholesterolemia
Urinary Tract Infections
Influenza Vaccine
COVID-21
Breast Cancer
Cancer Patients
Interstitial lung disease
Femtosecond Ophthalmic
Chronic Kidney Disease (CKD)
Melanoma
Tibial fracture
COVID-19
Acute Respiratory Syncytial Virus Infection
Viral Lung Infection Requiring Supplemental Oxygen (TILIA)
Focal segmental glomerulosclerosis (FSGS)
Nephropathy
Diabetes and Chronic Kidney Disease
chronic obstructive pulmonary disease (COPD)
Chronic Plaque Psoriasis
Atopic Dermatitis
Myasthenia Gravis
Proliferative Lupus Nephritis
Knee Osteoarthritis (KOA)
Ulcerative Colitis (UC)
Atrial fibrillation
Ischemic stroke
Persistent Cancer Pain
Institution
All
TMUH
WFH
SHH
Department
All
Colorectal Surgery
Oral Surgery
Orthopedics
Radiation Oncology
Dermatology
Plastic Surgery
Pulmonary Medicine/Sleep Clinic
Pulmonary Medicine
Obstetrics
Endocrinology and Metabolism
Gastroenterology
Pediatrics
Rheumatology
Family Medicine
Nephrology
Cardiology
Urology
Hematology and Oncology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Internal Medicine/Neurology
Hematology And Oncology
Cardiovascular Surgery
Infection
Neurology
Allergy, Immunology and Rheumatology
Principal Investigator
All
Wei Wang
Chia-Yu Wu
Jia-Lin, Wu
Long-Sheng Lu
Lee,Tsung-Ju
Li-Wei Tang
Pai-Chien Chou
Chao-Hua Chiu
Timothy Chiu
Shuen-Fu Weng
Wei-Yu Kao
Heng-Kien Au
Chun-Chao Chang
Chia-Yau Chang
Chi-Ching Chang
Shy-Shin Chang
Cheng Tiong
Han-Pin Kuo
Hsi-Hsien, Chen
Chun-Yao Huang
MING-CHE LIU
Yen-Lin Liu
Jia-Ruey Tsai
Yung-Hsiao,Chiang
Shih-Hsin Hsiao
Chi-Li Chung
Le-Ming Wang
Chien-Liang Wu
Jia-Ying Sung
Tzeon-Jye Chiou
Chun-Che Shih
Chia-Lun Chang
Kuo Yi-Jie
Fu-Lun Chen
Tsong-Yih Ou
Ming-Hsiung Hsieh
Mai-Szu Wu
Kang-Yun Lee
Woan-Ruoh Lee
Hou-Chang Chiu
Yu-Sheng Chang
Yung-Ho Hsu
Chih-Hwa Chen
Ming-Yao Chen
Chen Kuan-Yuan
Tzu-Tao Chen
Lung Chan
Po-Hao Feng
Chia-Lun Chou
Tsu-Yi Chao
Wei-Hong Cheng
Yao-Yu Hsieh
Protocol Title
Search
Clear
TMU-JIRB No.
Protocol Title
Indication
Institution
Department
Principal Investigator
Contact
N202402003
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Immunoglobulin A Nephropathy (IgAN)
Nephropathy
SHH
Nephrology
Mai-Szu Wu
Yun-Hui Wang
0972223815
N202206023
A PHASE 3 RANDOMIZED CONTROLLED STUDY OF RENAL AUTOLOGOUS CELL THERAPY (REACT) IN SUBJECTS WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE (REGEN-006)
Diabetes and Chronic Kidney Disease
SHH
Nephrology
Mai-Szu Wu
Yun-Hui Wang
0972223815
N201810016
A Phase III, Double-blind, Placebo controlled, Multi-center International Study of Neoadjuvant/adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung Cancer (AEGEAN)
Lung Cancer
SHH
Pulmonary Medicine
Kang-Yun Lee
Rong-Wei Jhou
0963969166
N201903127
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer
Lung Cancer
SHH
Pulmonary Medicine
Kang-Yun Lee
Rong-Wei Jhou
0963969166
N201912030
A Phase 3, Randomized, Doubleblind Study of Neoadjuvant Chemotherapy plus Nivolumab versus Neoadjuvant Chemothera py plus Placebo, followed by Surgical Resection and Adjuvant Treatment with Nivolumab o r Placebo for Participants with Resectable Stage II-IIIB Non-small Cell Lung Cancer
Lung Cancer
SHH
Pulmonary Medicine
Kang-Yun Lee
Cing-Mei Chen
0970746955
N202004125
A Phase III, Randomised, Controlled, Multi-centre, 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive, Resectable Non-small Cell Lung Cancer (NeoADAURA)
Lung Cancer
SHH
Pulmonary Medicine
Kang-Yun Lee
Cing-Mei Chen
0970746956
N202005083
A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination with AB122, and AB154 in Combination with AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer
Lung Cancer
SHH
Pulmonary Medicine
Kang-Yun Lee
Rong-Wei Jhou
0963969166
N202005083
A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination with AB122, and AB154 in Combination with AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer
Lung Cancer
SHH
Pulmonary Medicine
Kang-Yun Lee
Rong-Wei Jhou
0963969166
N202005126
A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)
Lung Cancer
SHH
Pulmonary Medicine
Kang-Yun Lee
Rong-Wei Jhou
0963969166
N202009060
A Phase II, Single Arm Study Assessing the Efficacy of Osimertinib in Combination with Savolitinib in Patients with EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer who have Progressed Following Treatment with Osimertinib (The SAVANNAH Study)
Lung Cancer
SHH
Pulmonary Medicine
Kang-Yun Lee
Rong-Wei Jhou
0963969166
1
2
3
4
5
6
7
8
9
10
11
12
13
/
13
TOP